Kelly Alford, MD
Nephrology · Kansas City, MONPI 1598724726
Payments from drug & device makers
What this record shows
4 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 48.2% of the total. That places this record below the midpoint for nephrology clinicians in MO, where the typical reported total is $723.
Across 4 payments — averaging $31.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$61
- Mallinckrodt Enterprises LLC$27
- GSK$22
- Vifor Pharma, Inc.$17
Across 30 payments — averaging $1921.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$53K
- Baxter Healthcare$4K
- Ardelyx, Inc.$1K
What the payments were for
- Food & beverage$6652%
- Education$6148%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
| GSK | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $17 |
How this compares
$127 in reported general payments places this provider in the 10th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 19 | $18,512 |
| Cinacalcet Hcl | 13 | $16,596 |
| EliquisApixaban | 12 | $7,515 |
| Sevelamer Carbonate | 22 | $5,518 |
| Torsemide | 52 | $1,442 |
| Calcium Acetate | 28 | $1,441 |
| Calcitriol | 47 | $1,390 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,054 |
| Lisinopril | 84 | $637 |
| Chlorthalidone | 22 | $609 |
| Terazosin Hcl | 19 | $601 |
| Metoprolol Succinate | 40 | $471 |
| Carvedilol | 54 | $471 |
| Telmisartan | 11 | $381 |
| Amlodipine Besylate | 98 | $377 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Kansas City
- Ahmed AwadKansas City$79K
- Richard CaplingKansas City$31K
- Tarek DarwishKansas City$8K
- Jignesh ShahKansas City$7K
- Adnan KhanKansas City$7K
- Robert GolderKansas City$5K
- Archana GoelKansas City$5K
- Ryan LustigKansas City$4K
- Pranavkumar DalalKansas City$4K
- Rafael TorosyanKansas City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.